Akadeum Life Sciences
PrivateLast Round
Seed Round
Jun 25, 2026
Total Funding Raised
$30.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Akadeum Life Sciences operates in Healthcare & Life Sciences and is based in Ann Arbor, Michigan. Its latest recorded funding round was a VC Round in June 2025.
Akadeum Life Sciences is a biotechnology company that has developed and commercialized a proprietary, flotation-based separation technology called Buoyancy Activated Cell Sorting (BACS™).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Akadeum Life Sciences Comparables
Compare Akadeum Life Sciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Applied Cells | 86% | |
| pluriSelect Life Science | 84% | |
| NanoCellect Biomedical | 84% |
For institutional investors. Book with your work email.
Akadeum Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jun 25, 2026 | ||||
| VC Round | Jun 3, 2025 | ||||
| Convertible Debt | May 30, 2023 | ||||
| Series B | Oct 12, 2021 | ||||
| Series A | Dec 19, 2019 | ||||
Debt | Feb 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Akadeum Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| eLab Ventures | Seed |
| Arboretum Ventures | VC Round, Series B |
| Beringea | VC Round, Series B |
| Berkeley Catalyst Fund | Series A, Series B |
| Genoa Ventures | Seed, Series A |
| Michigan Investment in New Technology Startups | Seed, Series A |
| Michigan Rise | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
Raised $2.1M in seed funding.
- Jan 12, 2026
CEO to present at Biotech Showcase 2026 on January 12, 2026.
For institutional investors. Book with your work email.
Akadeum Life Sciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Akadeum Life Sciences's valuation, stock price, and market status.
Is Akadeum Life Sciences a public or private company?
Akadeum Life Sciences is a private company.
What is the current stock price of Akadeum Life Sciences?
Akadeum Life Sciences is a private company, so its shares have no public market price. Caplight tracks Akadeum Life Sciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Akadeum Life Sciences worth (valuation)?
Valuation information for Akadeum Life Sciences is not publicly available.
Can I buy Akadeum Life Sciences stock?
Akadeum Life Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Akadeum Life Sciences's last funding round?
Akadeum Life Sciences's most recent funding round was Seed Round on June 25, 2026.
Who are the main investors in Akadeum Life Sciences?
Key investors in Akadeum Life Sciences include eLab Ventures, Arboretum Ventures, Michigan Capital Network, Michigan Strategic Fund.
Will Akadeum Life Sciences IPO soon?
No public IPO plans have been announced for Akadeum Life Sciences.
How can I track Akadeum Life Sciences secondary market activity?
Caplight tracks bids, offers, and trades in Akadeum Life Sciences's shares on secondary markets.